San Francisco, April 26, 2021 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular and other diseases, announced today that it is participating in the BIO Digital 2021 (BIO International Convention).
The conference is held annually and brings together the most innovative thinkers and leaders in biotechnology to provide opportunities through global partnerships, collaboration and thought leadership.
The conference will be held digitally and is taking place on June 14-18, 2021.
Recardio will be participating and presenting its latest advancements from its drug-based regenerative therapy and will give a future outlook on new therapies and expansion programs.
Recardio Inc. is a clinical-stage life science company focusing on therapies for cardiovascular and other diseases. The company is located in San Francisco, California, and is having its operations in USA and Europe. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration. Recardio is developing the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/ or contact email@example.com